Fig. 4: Longitudinal serum concentration of the AZD5396 and AZD8076 DMAbs expressed in vivo.
a–c, Sera collected at the indicated time points after DMAb administration were analyzed using a qualified quantitative binding assay to determine serum concentrations (ng ml−1) in individual participants who received a single dose of 0.5 mg or 1 mg on day 0 (indicated by the arrow) (a), two doses of 0.25 mg, 0.5 mg, 1 mg or 2 mg on days 0 and 3 (indicated by the arrows) (b) and four doses of 0.5 mg on days 0, 3, 28 and 31 (c) (indicated by the arrows). d, The mean serum concentrations of dose groups/cohorts are shown. The values shown represent the sum of serum concentrations of the two antibodies. The error bars represent the s.e.m. e, Maximum DMAb serum concentration according to group. The bars represent the mean concentrations (±s.e.m.) for each dose group; the points indicate the Cmax values for individual participants. f, AUC through week 72 according to group. The bars represent the mean concentrations (±s.e.m.) for each dose group.
